Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.05%. A quarter ago, it was expected that this drugmaker would post a loss of $11.50 per share when it actually produced a loss of $12.83, delivering a surprise of -11.57%.Over the last four quarters, the c ...

Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — BOSTON -- Vertex Pharmace ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq lost 0.56%.Heading into today, shares of the drugmaker had gained 0.13% over the past month, outpacing the Medical sector's loss of 4.31% and lagging the S&P 500's gain of 1.83% in that time.Investors will be eagerly watching for the performance ...

In its upcoming report, Vertex Pharmaceuticals (VRTX) is predicted by Wall Street analysts to post quarterly earnings of $4.13 per share, reflecting an increase of 1.2% compared to the same period last year. Revenues are forecasted to be $2.68 billion, representing a year-over-year increase of 7.8%. The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial e ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow experienced a rise of 0.65%, and the technology-dominated Nasdaq saw an increase of 0.26%.Shares of the drugmaker witnessed a gain of 3.2% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and the S&P 500's gain of 2%.Market participants will be closely fol ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.18% loss on the day. At the same time, the Dow lost 0.8%, and the tech-heavy Nasdaq gained 0.27%.Prior to today's trading, shares of the drugmaker had gained 3.89% over the past month. This has outpaced the Medical sector's loss of 3.03% and lagged the S&P 500's gain of 4.46% in that time.Market participants will ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq increased by 0.87%. The drugmaker's shares have seen a decrease of 0.75% over the last month, surpassing the Medical sector's loss of 3% and falling behind the S&P 500's gain of 4.87%. Analysts and investors alike will be keeping a close e ...

Vertex Pharmaceuticals (VRTX) closed at $465.08 in the latest trading session, marking a +0.48% move from the prior day. This move outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.38%. The drugmaker's stock has dropped by 6.66% in the past month, falling short of the Medical sector's loss of 2.49% and the S&P 500's gain of 2.06%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interes ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned -3.6%, compared to the Zacks S&P 500 composite's +2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Vertex falls in, has lost 1.5%. The key question now is: What could be the stock's future direction? ...